Umbilical cord blood transfusion refers to the transfusion of umbilical cord blood (including part of the blood in the placenta) collected by healthy mothers after delivery to patients to promote the improvement or recovery of hematopoietic function.
What is the principle?
Since the 90s of the 20th century, some scholars have studied hematopoietic cell growth factors in umbilical cord blood. It has been reported in the literature that umbilical cord blood plasma has the ability to support the self-renewal and proliferation of umbilical cord blood and bone marrow hematopoietic stem progenitor cells in vitro, while **peripheral blood plasma combined with G-CSF, GM-CSF, IL-1, IL-3, IL-6, IL-11, etc. cannot replace cord blood plasma, so it is speculated that umbilical cord blood plasma not only has high content of hematopoietic factors, but also contains hematopoietic factors that have not yet been recognized. Umbilical cord blood has the function of stimulating bone marrow hematopoiesis in vitro, and stimulating bone marrow hematopoiesis is the main purpose of umbilical cord blood transfusion.
What are the indications?
Primary and secondary myelodysplasia, such as aplastic anemia, myelosuppression after chemotherapy and radiotherapy for leukemia or other tumors, anemia due to EPO deficiency, and agranulocytosis of various causes, can be used as symptomatic or supportive**. There are no obvious contraindications to cord blood transfusion.
Precautions:
1. The whole process of collecting umbilical cord blood is strictly sterile and must not be contaminated.
2. The blood sample of the recipient patient must be cross-matched with the umbilical cord blood, and it can be transfused only after there is no agglutination.
3. Pregnant women must be healthy and must not have infectious diseases such as hepatitis.